U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07385079) titled 'Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma' on Sept. 23, 2025.
Brief Summary: This trial aimed to evaluate the efficacy of anlotinib hydrochloride combined with benmelstobart, induction chemotherapy, and concurrent chemoradiotherapy (IC+CCRT), versus a regimen of benmelstobart plus IC+CCRT, in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (LANPC).
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer
Intervention:
DRUG: Anlotinib Hydrochloride Capsules
Anlotinib hydrochloride (10mg, d1-d14) ...